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Abstract 
Rhabdomyolysis is a rare but potentially fatal complication of status asthmaticus. Since the first case was reported in 
1978, only a few dozen cases have been described till date. We performed a literature review with the aim to charac-
terize the pathophysiological basis of the occurrence of rhabdomyolysis in patients with status asthmaticus. Excessive 
exertion of respiratory muscles, hypoxia and acidosis, electrolyte imbalance, infections, some drugs used for asthma 
control, use of mechanical ventilation, prolonged cardiopulmonary resuscitation, higher age of the patient and some 
underlying diseases or genetic factors appear to be involved in its causation. In patients with status asthmaticus, it is 
important to pay more attention to these factors and to closely monitor creatine kinase levels in blood so as to ensure 
early detection of rhabdomyolysis.
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Background
Rhabdomyolysis, meaning destruction or disintegration 
of striated muscles, is characterized by muscle break-
down and necrosis that results in the leakage of intra-
cellular muscle constituents into the circulation and 
extracellular fluids [1]. The condition may range from an 
asymptomatic illness with elevation in the creatine kinase 
(CK) to a life threatening condition associated with 
extreme elevation in CK levels, electrolyte imbalance, 
acute renal failure and disseminated intravascular coagu-
lation. Rhabdomyolysis may occur in various congenital 
and acquired medical conditions, but rarely occurs as a 
complication of status asthmaticus.
The first reported case of rhabdomyolysis secondary to 
status asthmaticus was described by Chugh et al. in 1978 
[2]. Since then, only tens of cases of rhabdomyolysis fol-
lowing status asthmaticus have been reported in the last 
four decades. Most of these patients were adults; only six 
papers involved children and teenagers aged between 4 
and 18 years [3–8].
In this paper, we sought to characterize the patho-
physiological basis of the occurrence of rhabdomyolysis 
in patients with status asthmaticus. A literature search 
for relevant publications was performed; clinical investi-
gations, reviews and case reports were also included. A 
discussion on the factors that may precipitate the devel-
opment of this extremely rare complication of status 
asthmaticus is presented (Table 1).
Physiological factors
Exertion of respiratory muscles
Several factors may be involved in the pathogenesis of 
rhabdomyolysis, among which muscle exertion is the 
most common cause in both adults and children [9]. 
The underlying mechanism of rhabdomyolysis follow-
ing severe exertion appears to involve a combination of 
mechanical and thermal muscle injury and ATP deple-
tion [10]. Vigorous and repeated contractions of the res-
piratory and accessory muscles coupled with hypoxia 
appear to be the underlying mechanism of muscle dam-
age and cell necrosis in patients with status asthmaticus 
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[2, 4, 6, 7]. Risk factors for exertional rhabdomyolysis 
include, hypokalemia, sickle-cell trait [11], extreme heat 
and humidity, or pre-exertion fatigue. These conditions 
should be watched out for and avoided in patients with 
severe asthma attack. In addition, repeated coughing 
during the attack can also aggravate the severity of mus-
cular fatigue [2].
Hypoxia and acidosis
Generalized hypoxemia due to respiratory insufficiency 
secondary to status asthmaticus can lead to muscular 
ischemia and injury, which is regarded as another cause 
of rhabdomyolysis, due to its association with insuffi-
cient ATP production and sarcolemmal dysfunction [12]. 
Hypercapnia was a common finding in most cases of 
rhabdomyolysis associated with status asthmaticus. The 
occurrence of metabolic acidosis may identify patients 
at greater risk for rhabdomyolysis [7]. Some authors 
even point out that the combination of respiratory and 
metabolic acidosis may increase corticosteroid receptors 
and aggravate the risk of corticosteroid-induced muscle 
injury [3].
In most of the previous reported cases, vigorous exer-
tion of respiratory muscles, generalized muscle hypoxia, 
and metabolic and respiratory acidosis were often found 
together and considered to be the main factors leading to 
rhabdomyolysis [2, 4, 7, 13, 14].
Electrolyte imbalance
Electrolyte imbalance is a common complication in vari-
ous diseases, and status asthmaticus is no exception. 
Hypokalemia, hypophosphatemia, hyponatremia and 
even rapid correction of hyponatremia [15–17], have 
been reported to induce rhabdomyolysis. Among these, 
hypokalemia is considered to be the most notorious one. 
Hypokalemia is known to depolarize the muscle mem-
brane, inhibit the production and storage of glycogen in 
myocytes [1], and even limit vasodilatation in the mus-
cle microvasculature during exercise [18]. These appear 
to be the underlying mechanisms of the association 
between hypokalemia and exertional rhabdomyolysis. It 
is likely that electrolyte imbalance may trigger rhabdo-
myolysis during acute exacerbation of asthma; avoidance 
of hypokalemia in these patients is of great importance.
Infections
Asthma exacerbation can be triggered by various infec-
tions, especially that by viruses and mycoplasma pneu-
moniae. However, infection can also be a precipitating 
factor of rhabdomyolysis due to direct tissue damage, 
effect of toxins [19], inflammatory mediators [20], or 
associated fever, acidosis and dehydration [21, 22]. Path-
ogens reportedly associated with rhabdomyolysis include 
streptococcus [23], pneumococcus [21], legionella [24], 
influenza [25] (including recent pandemic of H1N1 sub-
type [26]), and mycoplasma pneumoniae [27]. Thus, we 




Glucocorticoids are one of the most important groups 
of medications used for asthma control. It is also well 
known to cause muscle injury, especially with prolonged 
therapy at high doses. Usually, glucocorticoid associ-
ated myopathy is characterized by a slowly-progressive, 
predominantly proximal muscle weakness and atrophy. 
Rhabdomyolysis occurring as a complication of gluco-
corticoid therapy has rarely been reported [3, 28]. The 
underlying mechanism of glucocorticoid-induced myo-
toxicity is not completely understood. In addition to 
suppressed protein synthesis and enhanced proteolysis 
of myofibrillar proteins, a recent review focused on one 
potential mechanism of glucocorticoid-induced apopto-
sis in skeletal muscle, i.e., through mitochondrial-medi-
ated and Fas-mediated apoptosis, leading to activation 
of proteasome in skeletal muscle, suppression of IGF-1 
signaling and generation of ceramide [29].
The development and the severity of glucocorticoid-
induced muscular injury shows much inter-individual 
variability and appears to depend on the treatment regi-
men, duration and dosage (repetitive burst treatment 
effects are considered worse than continuous treatment 
with the same dose) [30]. During short-term treatment 
with massive doses of glucocorticoids as frequently used 
in status asthmaticus, acute severe muscle injury may 
Table 1 Potential factors involved in the causation of rhab-
domyolysis secondary to status asthmaticus
Physiological factors Exertion of the respiratory muscles
Hypoxia and acidosis
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develop and is characterized by generalized fiber necrosis 
and rhabdomyolysis [30].
Administration of neuromuscular blocking agents 
(NMBAs) in patients with severe asthma attack that 
requires mechanical ventilation may lead to myopathy. 
The combined effects of the NMBAs and glucocorticoids, 
rather than either type of drug alone, could lead to myo-
pathic outcomes, which may range from asymptomatic 
CK elevation to myopathy with weakness [31–33] and 
even rhabdomyolysis [3]. Electromyographic findings 
suggest that the muscular denervated state due to the 
absence of cholinergic stimulation caused by NMBAs 
could potentiate the effect of glucocorticoids by inducing 
an increase in the cytoplasmic corticosteroid receptors 
[34, 35] and promote the depletion of myosin [36].
Inhalational corticosteroid therapy is much safer than 
systemic administration; there is no evidence of rhabdo-
myolysis directly induced by inhaled glucocorticoids.
β2‑Adrenergic agonists
β2-Adrenergic agonists, one of the main treatment 
modalities for asthma, are commonly used dur-
ing acute exacerbations. β2-Adrenergic agonists have 
been reported to induce muscle cramps and weakness, 
which is associated with varying degrees of CK eleva-
tion [37, 38]. However, rhabdomyolysis secondary to 
β2-adrenergic agonist therapy is indeed rare. Only in 
one case, rhabdomyolysis and acute renal failure after 
terbutaline overdose was reported, and the authors pro-
posed that the hyperkinetic effects of intense β2-receptor 
stimulation may have induced rhabdomyolysis [39]. The 
definitive mechanism is not clear, but tremor is a com-
mon side effect of β2-adrenergic agonist and hypokalemia 
can occur due to increased Na+/K+ ATPase activity in 
cases of β2-adrenergic agonist poisoning [40]. There are 
no records of rhabdomyolysis induced by nebulized β2-
adrenergic agonists.
Theophylline
Rhabdomyolysis is a rare complication of theophylline 
intoxication. Nearly all cases of theophylline related rhab-
domyolysis in previous case reports were associated with 
large doses [41–43]. Therapeutic dose of theophylline is 
unlikely to cause muscle injury. An 81-year-old asthmatic 
male who developed rhabdomyolysis after intravenous 
administration of 250  mg aminophylline appears to be 
an exception [44]. Development of rhabdomyolysis after 
theophylline occurred, presumably, at least in part, due 
to other complications of theophylline toxicity, such as 
profound hypokalemia, seizures or hypotension [45–47]. 
Therefore, in status asthmaticus patients on theophylline 
therapy, it is better to monitor serum theophylline levels 
and other features of theophylline toxicity such as sei-
zures and deranged potassium homeostasis.
Theophylline is often administered with drugs that may 
elevate the serum CK level (CK-elevating drugs) such as 
β2-adrenergic agonists and corticosteroids in status asth-
maticus patients. A study by Iwano et al. [48] suggested 
that combined treatment of theophylline and CK-elevat-
ing drugs may induce a synergistic increase in the serum 
CK levels. We speculate that it is the synergistic effect of 
several factors that leads to rhabdomyolysis during status 
asthmaticus; this may also explain why rhabdomyolysis is 
not commonly described in other severe respiratory dis-
eases such as exacerbation of COPD, in which exertion 
of the respiratory muscles, hypoxia and acidosis are com-
mon features.
Sedatives
Propofol is a popular anesthetic and sedative agent due 
to its rapid onset of action and short half-life, decrease in 
cerebral oxygen consumption, and the associated reduc-
tion in intracranial pressure [49]. Sedation with propofol 
is often required to facilitate ventilator synchrony dur-
ing mechanical ventilation in severe asthmatic patients. 
However, rhabdomyolysis, occurring as part of propofol-
related infusion syndrome (PRIS), has been sporadically 
reported in patients on prolonged propofol therapy in 
intensive care units (ICU) [50].
Various pathophysiological mechanisms of occurrence 
of rhabdomyolysis in PRIS have been postulated. Propo-
fol impairs the mitochondrial respiratory chain and pro-
duction of ATP, and further increases triglyceride load 
and disturbs the fatty acid oxidation. The deranged lipid 
and lactate metabolism in cardiac and skeletal muscles, 
along with impaired ATP synthesis, contributes to myo-
cytolysis, leading on to myocardial failure, arrhythmia, 
and rhabdomyolysis [51–54]. Pathological findings of 
cytolysis of skeletal and cardiac muscle cells in propofol 
infusion syndrome have been documented [55]. Other 
triggering factors include low carbohydrate supply, excess 
catecholamines and corticosteroid therapy in critically ill 
patients, which can cause myocyte injury, lipolysis, and 
increase circulating free fatty acids [52, 56].
On the whole, a lower propofol dose for a shorter dura-
tion with adequate carbohydrate intake is preferable. For 
adults, no more than 4  mg/kg of propofol per hour for 
a maximum of 48 h, is recommended [52]. Children are 
more prone to the development of PRIS due to low glyco-
gen storage and high dependence on fat metabolism [57].
In 2001, the US Food and Drug Administration placed 
a warning against use of propofol for long-term sedation 
in pediatric patients. The maximum permissible dose of 
propofol for sedation in the pediatric ICU is <5  mg/kg 
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per hour, under strict monitoring of blood lactate, myo-
globin and CK levels [58]. For patients suffering from 
status asthmaticus who need mechanical ventilation, 
propofol seems to be a high-risk factor for rhabdomyoly-
sis. It is important for clinicians to keep this undesirable 
complication in mind and to monitor for early warning 
signs, because prompt cessation of propofol infusion can 
reverse the impending consequences at an early stage 
[51]. Alternative drugs include lorazepam and mida-
zolam [49].
Antibiotics
Exacerbation of asthma is sometimes induced by lung 
infection, and antibiotics might be used in this setting. 
Administration of antibiotics such as fluoroquinolone 
[59], levofloxacin [60], clarithromycin [61], linezolid [62] 
and amphotericin B [63] is reportedly associated with 
rhabdomyolysis. Monitoring of serum CK levels is rec-
ommended alongside the use of any of these antibiotics 
in asthmatic patients.
Cytochrome P450 (CYP) 3A4 is known to oxidize a 
wide range of drugs, and effect drug metabolism. Clini-
cally important CYP3A4 inhibitors include itraconazole, 
ketoconazole, clarithromycin, erythromycin, etc. Rhab-
domyolysis is known to be a serious consequence of the 
co-administration of statins and CYP3A4 inhibitors. 
Concomitant use of clarithromycin with theophylline 
was reported to induce rhabdomyolysis in an asthmatic 
patient, by enhancing theophylline toxicity through inter-
fering with its metabolism [64]. Drug interactions may 
be most apparent when patients are stabilized on an 
affected drug and the CYP3A4 inhibitor is then added to 
the regimen [65]. For instance, a patient with corticoster-
oid-dependent asthma and allergic bronchopulmonary 
aspergillosis developed rhabdomyolysis after itraconazole 
supplementation to her long-time corticosteroid (defla-
zacort) treatment [66].
The drugs mentioned above are commonly used during 
asthma exacerbation; interaction between these drugs 
may potentially induce rhabdomyolysis during treatment 
of status asthmaticus. Nonetheless, status asthmaticus 
should be treated aggressively at an early stage in these 
patients to prevent respiratory muscle fatigue, muscle 
hypoxia, and to minimize the risk of postexertional rhab-
domyolysis [3, 4, 7].
Other therapeutic interventions
Resuscitation
A case of rhabdomyolysis that occurred after successful 
resuscitation from near-fatal asthma is on record [14]. 
According to the authors, the most likely etiology of 
rhabdomyolysis in this patient was vigorous and repeated 
contractions of respiratory muscles with muscular 
hypoxia; however, the association of cardiopulmonary 
resuscitation (CPR) and rhabdomyolysis should be fur-
ther assessed. Based on the two cases of post-resuscita-
tional rhabdomyolysis, the possible mechanisms may 
have been administration of excessive amounts of epi-
nephrine, massive cardioversion and prolonged CPR [67, 
68].
Mechanical ventilation
According to previous case reports, most cases of rhab-
domyolysis following status asthmaticus had a history of 
endotracheal intubation and mechanical ventilation [3, 4, 
6, 7, 14]. In a retrospective review, rhabdomyolysis, as a 
rare complication of asthma, showed a much higher fre-
quency (incidence: 8 %) in intubated asthmatic children 
than in non-intubated ones [5].
The available reports indicate that conditions associ-
ated with mechanical ventilation may play a contribu-
tory role in the development of rhabdomyolysis. Patients 
who need mechanical ventilation have more serious 
hypoxia and/or acidosis which is likely to contribute to 
the development of rhabdomyolysis. Secondly, propofol 
and sometimes NMBAs are needed to facilitate mechani-
cal ventilation. Concomitant use of these two alongside 
massive doses of glucocorticoids is likely to enhance the 
risk of muscle damage. Besides, prolonged immobiliza-
tion in patients under mechanical ventilation can induce 
tissue compression and muscle ischemia, which may also 
increase the risk of rhabdomyolysis [69, 70]. Addition-
ally, strategy of permissive hypercapnia is widely recom-
mended in patients with status asthmaticus to minimize 
hyperinflation and ventilator-induced lung injury. How-
ever hypercapnia may be a risk factor for rhabdomyolysis 
[3].
What should also be highlighted is the relationship 
between the development of rhabdomyolysis and baro-
trauma or ventilator-induced myotoxic cytokines. How-
ever, there are no correlational studies, and it may be a 
new direction to explore.
Patient factors
Underlying diseases
Repeated occurrence of rhabdomyolysis after asthmatic 
attacks in a patient with McArdle disease (myophosphor-
ylase deficiency) is on record [71]. In another case report, 
a soldier developed severe rhabdomyolysis after a mild 
acute asthma exacerbation. Further work-up revealed 
an underlying deficiency of type II carnitine palmitoyl-
transferase [72]. Both these underlying diseases belong 
to metabolic syndromes that are more sensitive to oxygen 
insufficiency and manifest as exercise intolerance. It sug-
gests that muscle damage would happen more easily dur-
ing asthma exacerbation given the underlying diseases.
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Besides these metabolic syndromes, some endo-
crine disorders (such as thyroid storm [73], diabetic 
ketoacidosis [74]) and autoimmune diseases (such as 
dermatomyositis [75]) have all been shown to promote 
rhabdomyolysis. Thus, the occurrence of rhabdomyolysis 
in the context of asthma exacerbations should warrant a 
further work-up for underlying diseases.
Age
In a retrospective review by Mehta et  al. [6], children 
who developed acute rhabdomyolysis tended to be older 
than those who did not develop rhabdomyolysis (median 
age 15 vs. 5  years, respectively). They inferred that the 
relatively lower muscle mass in the younger children may 
have prevented the development of exertional rhabdomy-
olysis. Most previous reports pertain to adults or teenag-
ers. Only one case report pertained to a 4-year-old boy, 
who is the youngest patient with this medical condition 
to the best of our knowledge [8].
Genetic heterogeneity
Most patients experience only one episode of rhabdomy-
olysis. However, in case of recurrent rhabdomyolysis, a 
history of exercise intolerance or a positive family history 
for neuromuscular disorders should be actively sought. 
Further investigations are also needed to identify any 
underlying genetic disorder [76].
The influence of genetic variations on statin-induced 
rhabdomyolysis has been investigated in a candidate gene 
association study and whole-genome sequencing [77]. 
We could not identify any studies that directly investi-
gated the effect of genetic heterogeneity on rhabdomyol-
ysis associated with status asthmaticus. However, several 
gene-specific single nucleotide polymorphisms (SNPs) 
are reportedly associated with severe exercise-induced 
muscle damage. These include CKMM Ncol, ACTN3 
R577X, and MYLK C37885A [78, 79].
This knowledge base may be useful for clinicians in 
identifying status asthmaticus individuals who are more 
susceptible to rhabdomyolysis. This is surely a new field 
for further exploration.
Conclusion
Rhabdomyolysis, a rare but potentially fatal complica-
tion of status asthmaticus, calls for more attention. Cur-
rent literature suggests that severity of hypoxia, acidosis 
and exertion of respiratory muscles, infections and/or 
electrolyte imbalance, the use of mechanical ventila-
tion, prolonged CPR, large dosages of corticosteroids or 
theophylline in combination with NMBAs or CYP3A4 
(such as macrolides), sedation with propofol, older age, 
and underlying myopathy may be the risk factors for 
rhabdomyolysis in patients with status asthmaticus. 
Research into genetic susceptibility to rhabdomyolysis 
is a new field for investigation. Clinicians should pay 
more attention to the clinical signs (muscle pain, mus-
cle edema, dark-colored urine) and monitor CK levels 
for early detection of this rare complication. Once rhab-
domyolysis occurs, it is important to prevent further 
muscle breakdown by adequate oxygenation and energy 
intake, correction of acidosis and electrolyte imbalance, 
change in sedative agent, etc. Early aggressive hydra-
tion may avoid deterioration and prevent irreversible 
damage.
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